Placental Protein 13 (Galectin-13) Polarizes Neutrophils Toward an Immune Regulatory Phenotype.
Apoptosis
/ genetics
Blood Donors
Cell Line, Tumor
Cell Polarity
/ drug effects
Coculture Techniques
Female
Galectins
/ genetics
Humans
Immunologic Factors
/ genetics
Male
Neutrophils
/ drug effects
Phagocytosis
/ drug effects
Phenotype
Placenta
/ metabolism
Plasmids
/ genetics
Pregnancy
Pregnancy Proteins
/ genetics
Reactive Oxygen Species
/ metabolism
Recombinant Proteins
/ metabolism
Signal Transduction
/ drug effects
Trophoblasts
/ metabolism
galectin
immunoregulation
neutrophils
placental protein 13
preeclampsia
pregnancy
tolerance
tumor permissive phenotype
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
10
2019
accepted:
20
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
9
3
2021
Statut:
epublish
Résumé
Termed as galectin-13, placental protein 13 (PP13) is exclusively expressed in the placenta of anthropoid primates. Research on PP13 in normal and pathologic pregnancies show alteration of PP13 concentrations in pregnancy affected by preeclampsia or gestational diabetes. Galectins are also described as potent immunomodulators, and PP13 regulates T cell function in the placenta. Therefore, this study aims to investigate the effects of PP13 on neutrophils; a cell type often ignored in pregnancy, but present in the uterus and placenta from the early stages of pregnancy. Since neutrophil function is dysregulated during pathologic pregnancies, a link between PP13 and neutrophil activity is possible. We determined that PP13 reduces the apoptosis rate in neutrophils. Also, PP13 increases the expression of PD-L1 and production of HGF, TNF-α, reactive oxygen species (ROS), and MMP-9 in these cells. This phenotype resembles one observed in permissive tumor neutrophils; able to sustain tissue and vessel growth, and inhibit T cell activation. At the same time, PP13 does not alter all neutrophil functions, i.e., extrusion of neutrophil extracellular traps, degranulation, phagocytosis, and ROS production following bacterial exposure. PP13 seems to play an essential role in regulating the activity of neutrophils in the placenta by polarizing them toward a placental-growth-permissive phenotype.
Identifiants
pubmed: 32117288
doi: 10.3389/fimmu.2020.00145
pmc: PMC7028707
doi:
Substances chimiques
Galectins
0
Immunologic Factors
0
LGALS13 protein, human
0
Pregnancy Proteins
0
Reactive Oxygen Species
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Informations de copyright
Copyright © 2020 Vokalova, Balogh, Toth, Van Breda, Schäfer, Hoesli, Lapaire, Hahn, Than and Rossi.
Références
Hum Immunol. 2005 Nov;66(11):1146-54
pubmed: 16571415
Front Immunol. 2018 Aug 14;9:1897
pubmed: 30154799
Front Immunol. 2015 Sep 14;6:471
pubmed: 26441976
Front Immunol. 2019 Jun 19;10:1240
pubmed: 31275299
Nature. 2015 Jun 18;522(7556):349-53
pubmed: 25985180
Am J Reprod Immunol. 2017 Mar;77(3):
pubmed: 28045214
Int J Mol Sci. 2017 Jul 20;18(7):
pubmed: 28726716
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9731-6
pubmed: 19497882
Blood. 2013 May 9;121(19):3900-7, S1-6
pubmed: 23532733
Am J Pathol. 1998 Oct;153(4):1139-47
pubmed: 9777945
J Leukoc Biol. 2007 Feb;81(2):449-57
pubmed: 17079651
Front Immunol. 2018 Aug 08;9:1661
pubmed: 30135684
Glycobiology. 2013 Jan;23(1):32-42
pubmed: 22942212
Placenta. 1999 Nov;20(8):703-10
pubmed: 10527825
J Immunol. 2006 Mar 1;176(5):3205-14
pubmed: 16493081
Protein Expr Purif. 2000 Jul;19(2):312-8
pubmed: 10873547
Cancer Res. 2003 Mar 15;63(6):1405-12
pubmed: 12649206
Cancers (Basel). 2019 Apr 19;11(4):
pubmed: 31010242
Science. 1991 Feb 15;251(4995):802-4
pubmed: 1846706
Fetal Diagn Ther. 2008;24(3):230-6
pubmed: 18753763
Front Immunol. 2014 Aug 20;5:348
pubmed: 25191322
Placenta. 2004 Aug;25(7):608-22
pubmed: 15193867
Biochem Biophys Res Commun. 2010 Feb 26;393(1):28-31
pubmed: 20097159
Arch Surg. 1999 Dec;134(12):1325-31; discussion 1331-2
pubmed: 10593330
Arch Gynecol Obstet. 2016 Nov;294(5):959-965
pubmed: 27161490
Lab Invest. 2016 Apr;96(4):428-38
pubmed: 26752743
Nat Rev Immunol. 2017 Aug;17(8):469-482
pubmed: 28627518
Sci Rep. 2015 Dec 17;5:18302
pubmed: 26673780
Virchows Arch. 2008 Oct;453(4):387-400
pubmed: 18791734
Arthritis Res Ther. 2014 Jun 13;16(3):R122
pubmed: 24928093
J Immunol. 2014 Sep 15;193(6):3070-9
pubmed: 25135830
Front Immunol. 2016 Dec 05;7:565
pubmed: 27994595
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7
pubmed: 18077379
Front Immunol. 2018 Jan 15;8:1999
pubmed: 29379509
Mucosal Immunol. 2016 Nov;9(6):1372-1383
pubmed: 26906405
J Leukoc Biol. 2000 Jul;68(1):125-30
pubmed: 10914499
J Biol Chem. 2002 May 31;277(22):19585-93
pubmed: 11916964
Dokl Biochem Biophys. 2013 Nov;453:312-5
pubmed: 24385104
Proc Soc Exp Biol Med. 1995 Sep;209(4):325-42
pubmed: 7638240
J Clin Endocrinol Metab. 1997 Mar;82(3):949-54
pubmed: 9062512
Blood. 1999 Aug 15;94(4):1165-73
pubmed: 10438703
Placenta. 2014 Nov;35(11):855-65
pubmed: 25266889
Cell Death Dis. 2018 Mar 19;9(4):422
pubmed: 29556041
Am J Reprod Immunol. 2017 Oct;78(4):
pubmed: 28703488
Front Immunol. 2018 Nov 13;9:2597
pubmed: 30483261
Reprod Sci. 2012 Jan;19(1):16-30
pubmed: 21989657
Cancer Lett. 2008 Jul 18;266(1):37-52
pubmed: 18406051
Dev Cell. 2013 Nov 25;27(4):373-86
pubmed: 24286824
Front Immunol. 2017 Jun 14;8:702
pubmed: 28659928
Blood. 2019 May 16;133(20):2159-2167
pubmed: 30898857